Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment

被引：9

作者：

Wang, Xiaoyuan ^{[1
]}

Ling, Xiaodong ^{[1
]}

Wang, Changhong ^{[1
]}

Zhang, Jinfeng ^{[1
]}

Yang, Yingnan ^{[1
]}

Jiang, Hao ^{[1
]}

Xin, Yanzhong ^{[1
]}

Zhang, Luquan ^{[1
]}

Liang, Hao ^{[1
]}

Fang, Chengyuan ^{[1
]}

Zheng, Dayong ^{[1
]}

Zhu, Jinhong ^{[2
]}

Ma, Jianqun ^{[1
]}

机构：

[1] Harbin Med Univ Canc Hosp, Dept Thorac Surg, Harbin 150040, Peoples R China

[2] Harbin Med Univ Canc Hosp, Dept Clin Lab, Biobank, Harbin 150040, Peoples R China

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2023年 / 72卷 / 06期

基金：

中国国家自然科学基金;

关键词：

Esophageal squamous cell carcinoma (ESCC); Neoadjuvant; Immunotherapy; Combination; Tumor microenvironment (TME); Immune; PREOPERATIVE CHEMORADIOTHERAPY; PD-L1; EXPRESSION; CANCER; IMMUNOTHERAPY; CAMRELIZUMAB; REGRESSION; PLACEBO;

D O I：

10.1007/s00262-022-03354-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Immune checkpoint inhibitors (ICIs) through programmed cell death 1 blockade improve the survival outcomes of patients with advanced esophageal squamous cell carcinoma (ESCC). Recently, the use of neoadjuvant immunotherapy for the treatment of ESCC has been gradually increasing. We aimed to evaluate the efficacy of neoadjuvant treatment of ICIs with chemotherapy and explore tumor microenvironment (TME) immune profiles of ESCC samples during neoadjuvant therapy. Methods Patients with previously untreated, resectable, locally advanced ESCC (stage II or III) in Harbin Medical University Cancer Hospital were enrolled. Each patient received two to four cycles of neoadjuvant ICIs combined with chemotherapy before surgical resection. The TME immune profiles of formalin-fixed paraffin-embedded tumor samples at baseline and after surgery were evaluated by multiplex staining and multispectral imaging. Results In all, 18 patients were enrolled, and all patients received surgery with R0 resection. The postoperative pathological evaluation indicated that 7 (38.9%) patients had a pathological complete response (pCR) and 11 (61.1%) patients had a partial response. The neoadjuvant therapeutic regimens had acceptable side effect profiles. The TME immune profiles at baseline observed higher densities of stroma CD3 + , PD-1 + , and PD-1 + CD3 + cells in pCR patients than in non-pCR patients. Comparing TME immune profiles before and after neoadjuvant treatment, an increase in CD8 + T cells and a decrease in CD163 + CD68 + M2-like macrophage cells were observed after neoadjuvant treatment. Conclusions Neoadjuvant ICIs combined with chemotherapy produced a satisfactory treatment response, demonstrating its anti-tumor efficacy in locally advanced ESCC. Further large-scale studies are required to understand the role of tumor immunities and ICIs underlying ESCC.

引用

页码：1619 / 1631

页数：13

共 53 条

[1] Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma [J].

Baba, Yoshifumi ;

Nomoto, Daichi ;

Okadome, Kazuo ;

Ishimoto, Takatsugu ;

Iwatsuki, Masaaki ;

Miyamoto, Yuji ;

Yoshida, Naoya ;

Baba, Hideo .

CANCER SCIENCE, 2020, 111 (09) :3132-3141

[2]

Bancewicz J, 2002, LANCET, V359, P1727

[3] The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation [J].

Bardhan, Kankana ;

Anagnostou, Theodora ;

Boussiotis, Vassiliki A. .

FRONTIERS IN IMMUNOLOGY, 2016, 7

[4] Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].

Becker, K ;

Mueller, JD ;

Schulmacher, C ;

Ott, K ;

Fink, U ;

Busch, R ;

Böttcher, K ;

Siewert, JR ;

Höfler, H .

CANCER, 2003, 98 (07) :1521-1530

[5] Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma [J].

Blank, Christian U. ;

Rozeman, Elisa A. ;

Fanchi, Lorenzo F. ;

Sikorska, Karolina ;

van de Wiel, Bart ;

Kvistborg, Pia ;

Krijgsman, Oscar ;

van den Braber, Marlous ;

Philips, Daisy ;

Broeks, Annegien ;

van Thienen, Johannes, V ;

Mallo, Henk A. ;

Adriaansz, Sandra ;

ter Meulens, Sylvia ;

Pronk, Loes M. ;

Grijpink-Ongering, Lindsay G. ;

Bruining, Annemarie ;

Gittelman, Rachel M. ;

Warren, Sarah ;

van Tinteren, Harm ;

Peeper, Daniel S. ;

Haanen, John B. A. G. ;

van Akkooi, Alexander C. J. ;

Schumacher, Ton N. .

NATURE MEDICINE, 2018, 24 (11) :1655-+

[6] CD4+ T cell help in cancer immunology and immunotherapy [J].

Borst, Jannie ;

Ahrends, Tomasz ;

Babala, Nikolina ;

Melief, Cornelis J. M. ;

Kastenmueller, Wolfgang .

NATURE REVIEWS IMMUNOLOGY, 2018, 18 (10) :635-647

[7] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J].

Boussiotis, Vassiliki A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1767-1778

[8] Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade [J].

Charoentong, Pornpimol ;

Finotello, Francesca ;

Angelova, Mihaela ;

Mayer, Clemens ;

Efremova, Mirjana ;

Rieder, Dietmar ;

Hackl, Hubert ;

Trajanoski, Zlatko .

CELL REPORTS, 2017, 18 (01) :248-262

[9] The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors [J].

Davis, Andrew A. ;

Patel, Vaibhav G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

[10] Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial [J].

Eyck, Ben M. ;

van Lanschot, J. Jan B. ;

Hulshof, Maarten C. C. M. ;

van der Wilk, Berend J. ;

Shapiro, Joel ;

van Hagen, Pieter ;

Henegouwen, Mark I. van Berge ;

Wijnhoven, Bas P. L. ;

van Laarhoven, Hanneke W. M. ;

Nieuwenhuijzen, Grard A. P. ;

Hospers, Geke A. P. ;

Bonenkamp, Johannes J. ;

Cuesta, Miguel A. ;

Blaisse, Reinoud J. B. ;

Busch, Olivier R. ;

Creemers, Geert-Jan M. ;

Punt, Cornelis J. A. ;

Plukker, John Th M. ;

Verheul, Henk M. W. ;

Bilgen, Ernst J. Spillenaar ;

van der Sangen, Maurice J. C. ;

Rozema, Tom ;

Ten Kate, Fiebo J. W. ;

Beukema, Jannet C. ;

Piet, Anna H. M. ;

van Rij, Caroline M. ;

Reinders, Janny G. ;

Tilanus, Hugo W. ;

Steyerberg, Ewout W. ;

van der Gaast, Ate .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1995-+

← 1 2 3 4 5 6 →